/ Aurobindo Pharma receives USFDA Approval For Atomoxetine Capsules ~ Ways2Capital|Stock Tips|Stock Market Tips|Intraday Stock Tips|Stock Trading Tips|NSE BSE Tips

Wednesday, 31 May 2017

Aurobindo Pharma Limited has received final approval from the US Food & Drug Administration (USFDA) to manufacture Atomoxetine capsules, 10 mg, 18 mg, 25mg, 40 mg, 60 mg, 80 mg and 100 mg.

Atomoxetine capsules are the AB rated generic equivalent of EliLilly and Company’s Strattera capsules.

Atomoxetine capsules are indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD). The approved product has an estimated market size of US$ 1.1 billion for the 12 months ending March 2017 .

This is the 116th  ANDA (including 14 tentative approvals) to be approved out of Unit III formulation. facility in Hyderabad, India used for manufacturing oral products. Aurobindo now has a total of 320ANDA approvals (286 Final approvals including 16 from Aurolife Pharma LLC and 34 tentative approvals) from USFDA.

For Quick Trial – 8962000225 ✔ 
or mail us here: info@ways2capital.com
or visit http://www.ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 ✔ 
Give a Missed Call for Free Trial - 09699997717 ✔